Category - Developments

Developments

BriaCell immunotherapy/KEYTRUDA combination increases anti-tumor activity in early trial

BriaCell Therapeutics (TSX-V:BCT) (OTCQB:BCTXF) announced that early Phase 1/2a data suggest its Bria-IMT immunotherapy, combined with the checkpoint inhibitor KEYTRUDA, demonstrated additive or synergistic anti-tumor...

April 3, 2019

Developments

Evogene to develop next generation medical cannabis products

Evogene (NASDAQ, TASE:EVGN) has established a new subsidiary, Canonic, to develop next generation medical cannabis products. Evogene has been evaluating the medical cannabis field for more than a year, including market...

April 3, 2019

Developments

BDO USA acquires of BioProcess Technology Consultants

BDO USA acquired BioProcess Technology Consultants, a provider of chemistry, manufacturing and controls (CMC) consulting services to the global biopharmaceutical industry. The acquisition of BioProcess bolsters BDO’s...

April 3, 2019

Developments

Ziopharm glioblastoma program gets FDA fast track designation

Ziopharm Oncology’s (NASDAQ:ZIOP) controlled IL-12 program received FDA fast track designation for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. Controlled IL-12 consists of IL-12...

April 3, 2019

Developments

Idera Pharma presents positive Phase 1 data of tilsotolimod for solid tumors

Idera Pharma (NASDAQ:IDRA) presented results of its Phase 1 trial of tilsotolimod as monotherapy in patients with various refractory solid tumors. Tilsotolimod is a toll-like receptor 9 agonist that activates cancer...

April 3, 2019

Developments

ADMA Biologics ASCENIV gets FDA approval

ADMA Biologics’ (NASDAQ:ADMA) ASCENIV has received FDA approval for the treatment of primary humoral immunodeficiency disease (PI) in adults and adolescents. The approval is based on results of a pivotal Phase 3...

April 2, 2019

Developments

Advaxis reports positive initial Phase 1 data for cancer vaccine

Advaxis’ (NASDAQ:ADXS) ADSX-NEO has demonstrated significant anti-tumor activity in a Phase 1 study of patients with certain types of advanced or metastatic solid tumors. ADXS-NEO is a live, attenuated Listeria...

April 2, 2019

Developments

Ocutrx Vision receives second patent for augmented reality glasses eye tracking technology

Closely-held Ocutrx Vision Technologies announced issuance of the company’s second U.S. patent, which will protect the company’s unique eye tracking technology for patients with macular degeneration and other low vision...

April 2, 2019

Developments

Imagin Medical successfully completes i/Blue functional unit assembly

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart: DPD2) has completed assembly of its i/Blue Imaging System’s functional unit, which has met the company’s pre-established performance expectations. The...

April 2, 2019

Developments

Aphria launches CBD-based products in Germany

Aphria (TSX:APHA; NYSE:APHA) has launched CannRelief, a cannabidiol (CBD)-based nutraceutical and cosmetics line, through its subsidiary Aphria Deutschland. Featuring hemp-derived CBD, CannRelief products are produced...

April 1, 2019

Category - Developments

BriaCell immunotherapy/KEYTRUDA combination increases anti-tumor activity in early trial

Evogene to develop next generation medical cannabis products

BDO USA acquires of BioProcess Technology Consultants

Ziopharm glioblastoma program gets FDA fast track designation

Idera Pharma presents positive Phase 1 data of tilsotolimod for solid tumors

ADMA Biologics ASCENIV gets FDA approval

Advaxis reports positive initial Phase 1 data for cancer vaccine

Ocutrx Vision receives second patent for augmented reality glasses eye tracking technology

Imagin Medical successfully completes i/Blue functional unit assembly

Aphria launches CBD-based products in Germany

General

More